In Vivo Evaluation of a Gastro-Resistant HPMC-Based “Next Generation Enteric” Capsule* (Rump A, Kromrey M-L, Scheuch E, et al. Pharmaceutics 2022;14:doi.org/10.3390)
This downloadable summary features findings from a peer-reviewed study published in Pharmaceutics (2022), evaluating the in vivo performance of Capsugel® Enprotect® capsules—a next-generation, gastro-resistant HPMC-based dosage form. To address the challenge of delivering acid-sensitive APIs and fragile therapeutics beyond the stomach’s harsh environment and ensuring targeted absorption in the distal small intestine, the study evaluated capsule disintegration and gastro-resistance using two complementary techniques. For the first time, magnetic resonance imaging (MRI) and caffeine detection in saliva—two well-established but distinct methodologies—were combined to assess the in vivo performance of gastro-resistant capsules in fasted subjects.
Download the Summary Now
Gain quick insights into this innovative Pharmaceutics study on Capsugel® Enprotect® capsules. Learn how this innovative dosage form was evaluated in vivo using a novel combination of imaging and analytical techniques.
*Dr Vincent Jannin, Director R&D and Head of Innovaform® Accelerator in Colmar, France, is a co-author of this study and leader of the working group on “Advanced formulations”
